5-Fluorouracile

DRUG3 trials

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Groupe Oncologie Radiotherapie Tete et Cou, Assistance Publique Hopitaux De Marseille

Conditions

Head and Neck Squamous Cell CarcinomaMetastatic Colorectal CancerPatients With Head and Neck Cancer (ORL)

Phase 2

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors

TerminatedNCT01858662

Cliniques universitaires Saint-Luc- Université Catholique de LouvainMetastatic Colorectal Cancer

Start: 2014-01-31End: 2015-11-30Updated: 2016-04-15

Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC

CompletedNCT02268695

Groupe Oncologie Radiotherapie Tete et CouHead and Neck Squamous Cell Carcinoma

Start: 2014-10-10End: 2021-12-31Updated: 2022-08-23

Phase 4

Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy

CompletedNCT02484677

Assistance Publique Hopitaux De MarseillePatients With Head and Neck Cancer (ORL)

Start: 2015-07-15End: 2023-05-25Updated: 2023-05-26

Related Papers

Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

2025-08-21

Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma

CPT Pharmacometrics & Systems Pharmacology2024-12-252 citations

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.

2021-03-05134 citations

TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Journal of Clinical Oncology2020-05-2024 citations

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Journal of Clinical Oncology2019-05-2082 citations

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma.

Journal of Clinical Oncology2015-05-2040 citations

Randomized phase II studies comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining bevacizumab or cetuximab with FOLFOX or FOLFIRI.

Journal of Clinical Oncology2015-01-20